ESR1 and breast cancer: Given that CPT1A-enhanced FAO can promote the acquisition of malignant phenotypes such as cell proliferation and tamoxifen resistance in ER-positive BC cells, CPT1A-FAO might be an effective target for overcoming tamoxifen resistance in BC cells.